Product Information
COLISTIMETHATE 150 MG VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $15.4867 per EA under NDC 63323039306. Its NADAC has been published 176 times since Nov 28, 2013.
FDA first approved this application on Apr 17, 2008. Its Orange Book therapeutic-equivalence code is AP.
Strength
150 mg/2mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323039306
Classification
Generic
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
5/20/2026
Active Ingredients
COLISTIMETHATE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA065364FDA Approved
4/17/2008
TE Code
AP
On Market Since
12/4/2009
Pharmacological Classes
Price Statistics
The NADAC for COLISTIMETHATE 150 MG VIAL has been published 176 times since Nov 28, 2013, and over the history we have for it it has declined 4.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.4867 per EA |
|---|---|
| All-time high | $27.0680 (Nov 12, 2014) |
| All-time low | $15.4867 (May 20, 2026) |
| 52-week high | $17.9620 |
| 52-week low | $15.4867 |
| Median price | $16.8900 |
| Average price | $19.2447 |
| Largest weekly change | +67.1% (Jan 22, 2014) |
| Weeks tracked | 176 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
COLISTIMETHATE SODIUM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Polymyxin-class Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of COLISTIMETHATE 150 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for COLISTIMETHATE 150 MG VIAL, manufactured by Fresenius Kabi USA, LLC, is $15.4867 per EA (NDC 63323039306), effective Sep 30, 2026.
How has the price of COLISTIMETHATE 150 MG VIAL changed over time?
Over the history we have for it, the NADAC for COLISTIMETHATE 150 MG VIAL has declined 4.4%. It has been tracked across 176 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for COLISTIMETHATE 150 MG VIAL?
Since Nov 28, 2013, the NADAC for COLISTIMETHATE 150 MG VIAL has ranged from a low of $15.4867 (May 20, 2026) to a high of $27.0680 (Nov 12, 2014), with a median of $16.8900 per EA.
Are there cheaper alternatives to COLISTIMETHATE 150 MG VIAL?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as COLISTIMETHATE 150 MG VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures COLISTIMETHATE 150 MG VIAL?
COLISTIMETHATE 150 MG VIAL (NDC 63323039306) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.